Improved Patient Outcomes, Inc., Recognized as Patient Engagement Innovator

Share Article

Improved Patient Outcomes, Inc., is garnering attention for its multi-channel, two-way patient engagement platform.

Improved Patient Outcomes, Inc., (IPO) was recently recognized as one of the most innovative companies in the pharmaceutical industry by editors of PM360.

In its annual Innovations Issue, PM360 identified the significant role that IPO is playing in improving patient engagement and outcomes, especially in the area of medication adherence.

The foundation of IPO—a joint venture between Duke University Department of Medicine and the private sector—is a rich library of dynamic, evidence-based behavioral intervention content for more than 90 disease states. The $80 million body of research has been developed at Duke University over the past 18 years under the leadership of Hayden Bosworth, PhD.

“We embarked on this venture realizing how invaluable the content would be to pharmaceutical companies, providers, health plans and employers—all of whom are working diligently to improve outcomes and value at the same time drive down costs in healthcare,” said Greg A. Muffler, IPO Chief Executive Officer and Founder. “As an industry, we have focused a great deal of attention on operations and process improvement, which are critical to transforming healthcare. However, we believe that even more substantial benefits will be realized when we are able to engage patients more effectively and modify their behaviors,” Muffler added.

The content is delivered through a multi-channel, two-way patient engagement platform, which includes mobile, web, SMS, email, IVR, live call, face-to-face and direct mail capabilities. Leveraging over a hundred predictive indicators, IPO can determine the optimal messaging and timing for patient engagement at the individual patient level.

The company’s targeted behavioral intervention approach is showing a boost in medication adherence of 15 to 20 percent.

In one program, patients with Acute Coronary Syndrome (ACS) from four different Veterans Administration Medical Centers (VAMC) were randomized to a one-year intervention program comprised of pharmacist-led medication reconciliation and tailoring, patient education, collaborative care between pharmacist and primary care provider and cardiologist and voice messaging. In the intervention group, 87 percent of patients were adherent compared to 72 percent in the usual care group. The median pharmacy refill adherence was also higher in the intervention group.

In another project, in a Pharma Foundation-funded pilot, Medicaid patients with high cardiovascular disease (CVD) risk received tri-weekly texts/SMS, as well as monthly calls, to help address CVD-related medication adherence.

“This Medicaid population is typically a challenging group of individuals to reach with low incomes and health literacy, but the results have been impressive,” Muffler said. “Even after 12 months of being enrolled in IPO’s program, more than 90 percent of the patients were still engaged, and we are seeing positive results.”


About Improved Patient Outcomes
IPO, Inc. is a leader in the medication adherence and patient outcomes space with over 90 disease states of evidence-based behavioral content deployed via a multi-channel patient engagement platform. IPO, Inc.. is headquartered in Raleigh, N.C.

About PM360
PM360 is the premier magazine for marketing decision makers in the pharmaceutical, biotech and medical device industries. Published monthly, PM360 focuses on delivering the full spectrum of practical information necessary for product managers and pharma marketing professionals to succeed in the complex and highly-regulated healthcare environment.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Carol Dorn Sanders
Visit website